Stay updated on CMP-001 Combo With Nivolumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the CMP-001 Combo With Nivolumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CMP-001 Combo With Nivolumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating that patients participating in the clinical research study will now receive nivolumab in combination with CMP-001 for a total of 8 weeks prior to surgery, instead of the previous 7 weeks.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:20.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of what eligibility criteria entail for clinical research participation.
    Difference
    47%
    Check dated 2024-05-22T21:10:03.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:39:35.000Z thumbnail image

Stay in the know with updates to CMP-001 Combo With Nivolumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CMP-001 Combo With Nivolumab in Melanoma Clinical Trial page.